Lipocine Inc (NASDAQ:LPCN) target price raised to $25.00, reported today by HC Wainwright
- Updated: October 7, 2016
Yesterday Lipocine Inc (NASDAQ:LPCN) traded 29.74% higher at $4.17. LPCN’s 50-day average is $3.80 and its two hundred day average is $6.52. With the last stock price close down -16.99% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was up over the average, with 11,445,788 shares of LPCN changing hands over the typical 402,229
Lipocine Inc (NASDAQ:LPCN) had its target price raised to $25.00 by HC Wainwright in a report released Friday October 07, 2016. The new target price indicates a possible upside of 5.00% based on the company's last closing price.
Previously on 06/23/2015, Canaccord Genuity reported on Lipocine Inc (NASDAQ:LPCN) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 0.86%.
With a total market value of $0, Lipocine Inc has 52 week low of $2.51 and a 52 week high of $14.80 .
About Lipocine Inc (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.